EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Key role of glutamine metabolism in persistence of leukemic cells upon exposition to FLT3 tyrosine kinase inhibitors

Raeeka Khamari, Claire Degand, Quentin Fovez, Anne Trinh, Axel Chomy, William Laine, Salim Dekiouk, Bart Ghesquiere, Bruno Quesnel, Philippe Marchetti, Salomon Manier, J Kluza

Experimental Hematology · 2024

DOI: 10.1016/j.exphem.2024.104253 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimental Hematology, 2024. Verfasst von Raeeka Khamari und 11 weiteren Autor:innen. Beteiligte Einrichtung: Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Glutamine, Protein Kinase Inhibitors, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Daiichi Sankyo Europe, Ligue Nationale Contre Le Cancer, Agence Régionale de Santé Hauts-de-France.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemias are a group of hematological malignancies characterized by a poor prognosis for survival. The discovery of oncogenic mutations in the FMS-like tyrosine kinase 3 (FLT3) gene has led to the development of tyrosine kinase inhibitors such as quizartinib. However, achieving complete remission in patients remains challenging because these new tyrosine kinase inhibitors (TKIs) are unable to completely eradicate all leukemic cells. Residual leukemic cells persist during quizartinib treatment, leading to the rapid emergence of drug-resistant leukemia. Given that mitochondrial oxidative metabolism promotes the survival of leukemic cells after exposure to multiple anticancer drugs, we characterized the metabolism of leukemic cells that persisted during quizartinib treatment and developed metabolic strategies to eradicate them. In our study, employing biochemical and metabolomics approaches, we confirmed that the survival of leukemic cells treated with FLT3 inhibitors critically depends on maintaining mitochondrial metabolism, specifically through glutamine oxidation. We uncovered a synergistic interaction between the FLT3 inhibitor quizartinib and L-asparaginase, operating through antimetabolic mechanisms. Utilizing various models of persistent leukemia, we demonstrated that leukemic cells resistant to quizartinib are susceptible to L-asparaginase. This combined therapeutic strategy shows promise in reducing the development of resistance to FLT3 inhibitors, offering a potential strategy to enhance treatment outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

fms-Like Tyrosine Kinase 3GlutamineProtein Kinase InhibitorsLeukemia, Myeloid, AcutePhenylurea CompoundsHumansDrug Resistance, NeoplasmMitochondriaBenzothiazolesCell Line, TumorAnimalsMiceTyrosine Kinase Inhibitors

Substanzen

fms-Like Tyrosine Kinase 3GlutamineProtein Kinase InhibitorsFLT3 protein, humanquizartinibPhenylurea CompoundsBenzothiazolesTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France.
  • Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France; Centre de Bio-Pathologie, Banque de Tissus, CHU of Lille, Lille, France.
  • Department of Oncology, Metabolomics Core Facility, Center for Cancer Biology, KU Leuven, Leuven, Belgium.
  • Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France; Hematology Department, CHU of Lille, Lille, France.
  • Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France. Electronic address: jerome.kluza@inserm.fr.

Förderung

  • Daiichi Sankyo Europe
  • Ligue Nationale Contre Le Cancer
  • Agence Régionale de Santé Hauts-de-France
  • Université de Lille
  • Inserm Transfert

Zitieren

APA

Khamari, R., Degand, C., Fovez, Q., Trinh, A., Chomy, A., Laine, W., Dekiouk, S., Ghesquiere, B., Quesnel, B., Marchetti, P., Manier, S., & Kluza, J. (2024). Key role of glutamine metabolism in persistence of leukemic cells upon exposition to FLT3 tyrosine kinase inhibitors. Experimental Hematology. https://doi.org/10.1016/j.exphem.2024.104253

Vancouver

Khamari R, Degand C, Fovez Q, Trinh A, Chomy A, Laine W, et al. Key role of glutamine metabolism in persistence of leukemic cells upon exposition to FLT3 tyrosine kinase inhibitors. Experimental Hematology. 2024. doi:10.1016/j.exphem.2024.104253

BibTeX
@article{Khamari2024,
  author = {Khamari, Raeeka and Degand, Claire and Fovez, Quentin and Trinh, Anne and Chomy, Axel and Laine, William and Dekiouk, Salim and Ghesquiere, Bart and Quesnel, Bruno and Marchetti, Philippe and Manier, Salomon and Kluza, J},
  title = {Key role of glutamine metabolism in persistence of leukemic cells upon exposition to FLT3 tyrosine kinase inhibitors},
  journal = {Experimental Hematology},
  year = {2024},
  doi = {10.1016/j.exphem.2024.104253}
}
Kostenlos starten →